Physician profile
Edward M Lee
NPI 1568466431
$8,235.22
in general payments reported to CMS, 2019-2025
27 companies · $811 in 2025
The $811 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $906 · 2020: $146 · 2021: $255 · 2022: $487 · 2023: $620 · 2024: $5,010 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $3,405 · Food and Beverage: $3,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $3,405.32 |
| Food and Beverage | $3,035.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $4,104.89 | 2019-2024 | Aveir, Optis |
| Medtronic, INC. | $621.02 | 2022-2025 | Micra, Linq II |
| Amgen INC. | $531.59 | 2019-2025 | Repatha, Repatha |
| E.R. Squibb & Sons, L.L.C. | $493.59 | 2019-2025 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $352.49 | 2019-2025 | Jardiance |
| Novartis Pharmaceuticals Corporation | $304.55 | 2023-2025 | |
| Abiomed | $262.21 | 2025 | |
| Pfizer INC. | $246.49 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $229.87 | 2019-2024 | |
| Shockwave Medical, INC | $176.49 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $154.48 | 2019-2025 | Lifevest |
| Actelion Pharmaceuticals US, INC. | $122.14 | 2019 | |
| Merck Sharp & Dohme LLC | $110.91 | 2021-2023 | Verquvo |
| Janssen Pharmaceuticals, INC | $104.28 | 2019-2023 | Xarelto |
| Chiesi USA, INC. | $56.04 | 2019-2025 | Juxtapid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $51.78 | 2019 | |
| Boston Scientific Corporation | $50.89 | 2019-2023 | Bodyguardian |
| Kestra Medical Technology Services, INC. | $38.75 | 2024 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $34.92 | 2024 | Arcalyst |
| Regeneron Healthcare Solutions, INC. | $33.20 | 2025 | Evkeeza |
| W. L. Gore & Associates, INC. | $31.96 | 2019 | |
| Scpharmaceuticals INC. | $25.53 | 2025 | |
| Impulse Dynamics (USA) INC. | $22.33 | 2023 | Optimizer |
| Atricure, INC. | $20.95 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $20.37 | 2023 | Farxiga |
| Allergan, INC. | $18.47 | 2019 | |
| Edwards Lifesciences Corporation | $15.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.